Pivekimab Sunirine Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Anti-CD123 ADC IMGN632, Antibody-drug Conjugate IMGN632, CD123-targeted ADC IMGN632, IMGN 632, IMGN-632, IMGN632

Filter by location:

Seattle, Washington1 trial

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Fred Hutch/University of Washington Cancer Consortium

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.